Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions
|
|
- Adelia Long
- 5 years ago
- Views:
Transcription
1 16 April 2018 Analyst Lafitani Sotiriou Authorisation TS Lim Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously $52.10) GICS Sector Diversified Financials Expected Return Capital growth 12.9% Dividend yield 6.4% Total expected return 19.3% Company Data & Ratios Enterprise value Market cap $1.74bn $1.96bn Issued capital 46.6m Free float 100% Avg. daily val. (52wk) $9.76m 12 month price range $41.99-$57.34 Price Performance (1m) (3m) (12m) Price (A$) Absolute (%) Rel market (%) Over 6% yield, with upside in market rally PPT has delivered a disappointing quarterly update which includes a lost mandate and unfavourable market movements. However, the share price is already down over -21% since the highs seen as recent as February and we believe this has more than captured the earnings revision seen today. We believe now is a good time to revisit the stock with over a 6% dividend yield on offer, and while there is negative sentiment on the stock from what we see as largely a one-off negative flow in the period and from a difficult period in the share market with volatility and a general decline across the board. However, the ASX200 is already up ~2% this June quarter, providing an early encouraging sign, which if maintained, provides the catalyst for a potential positive rerating. Quarterly highlights PPT has released its March quarter net-flows and FUM update, highlights include: Closing FUM of $30.2 billion. vs BPe $32.8 billion; Net-flows of -$1.3 billion vs. BPe -$0.1 billion, due to a lost mandate; and Market and other flows of -$1.3 billion, vs. BPe +$100m. Earnings revisions Following the March quarter update, we have downgraded our underlying EPS estimates by -2.9%, -9.5%, and -8.7% for FY18, FY19 and FY20 respectively. The changes are driven by lower share market and net-flow levels versus expectation. The ASX200 was down -5% during the period, and there was a lost institutional mandate which we see as one-off. Following the revisions our revised Price Target is $47.50 per share (previously $52.10), with an upgrade to our recommendation to Buy (previously Hold). Absolute Price $60.00 $55.00 $50.00 $45.00 $40.00 $35.00 $30.00 Apr 16 Oct 16 Apr 17 Oct 17 Apr 18 SOURCE: IRESS PPT S&P 300 Rebased BELL POTTER SECURITIES LIMITED ACN AFSL Earnings Forecast Year end June e 2019e 2020e Revenue (A$m) EBITDA (A$m) NPAT (reported) (A$m) NPAT (adjusted) (A$m) EPS (adjusted) (cps) EPS growth (%) 7% 3% -2% 6% PER (x) Price/CF (x) EV/EBITDA (x) Dividend ( ps) Franking (%) 100.0% 100.0% 100.0% 100.0% Yield (%) 6.3% 6.4% 6.5% 6.9% ROE (%) 22.1% 22.0% 21.0% 21.8% SOURCE: BELL POTTER SECURITIES ESTIMATES DISCLAIMER: THIS REPORT MUST BE READ WITH THE DISCLAIMER ON PAGE 6 THAT FORMS PART OF IT. Page 1
2 Quarterly FUM Figure 1 - Perpetual Investments quarterly FUM and net-flows Perpetual Investments FY16 1Q 2Q 3Q 4Q FY17 1Q 2Q 3Q 4Qe FY18e 1Qe 2Qe 3Qe 4Qe FY19e FY20e Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Jun-17 Sep-17 Dec-17 Mar-18 Jun-18 Jun-18 Sep-18 Dec-18 Mar-19 Jun-19 Jun-19 Jun-20 Asset Type Australian Equities Open Net-flow s Market & Other Close Global Equities Open Net-flow s Market & Other Close Cash & Fixed Income Open Net-flow s Market & Other Close Other Open Net-flow s Market & Other Close LIC Open Net-flow s Market & Other Close Total Open Net-flow s Market & Other Close Channel Retail Open Net-flow s Market & Other Close Intermediary Open Net-flow s Market & Other Close Institutional Open Net-flow s Market & Other Close All Channels Open Net-flow s Market & Other Close SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Page 2
3 Perpetual overview Company description Perpetual is a diversified financial, with about half of earnings attributed to Perpetual Investments (product manufacturer and distribution), with the two remaining quarters split between Private Wealth (fiduciary and financial advisory) and Corporate Trust (corporate trustee). In December 2013, PPT acquired TRU, with its business to fall within the three divisions noted below: Perpetual Investments is a traditional product manufacturer with some structured products. We believe the business has scale, a strong brand and is well positioned to capture a market recovery. Perpetual Private is split across financial advisory and fiduciary services. The income is less volatile as it is diversified with varying income structures, including fee based services which provides greater stability. Corporate Trust is the largest provider of corporate trustee services and transaction support in Australia. Investment Strategy We currently have a Hold recommendation given our valuation, although would review this on share price weakness. Risks Key risks for the stock include: Key people risk Similar to other wealth management businesses, the loss of any key investment personnel may result in the loss of investment mandates; Performance risk Investors are wary of investment managers that charge active management fees and that have underperformed the index over a prolonged period of time. It is important for Perpetual to maintain reputable performance metrics across its product offering; Financial Advice risk On the back of Storm Financial, Managed Investment Schemes and other well-known collapses in the industry, there is an added focus on any unsavoury practices and Perpetual will do well to steer clear of any negative headlines; and Market Risk PPT is exposed to adverse and sudden stock market changes, whether driven by natural or manmade disaster or event. Page 3
4 Interim earnings and revisions Figure 2 - Interim earnings INTERIM INCOME STATEMENT Y/e June 30 ($m) H17 2H H18 2H18e 2018e 1H19e 2H19e 2019e 1H20e 2H20e 2020e Sales revenue EBITDA Depreciation & Amortisation Equity Grant Amortisation EBIT Net Interest Pre-tax profit Tax Adjusted profit One-off items Reported net profit SEGMENTALS Y/e June H17 2H H18 2H18e 2018e 1H19e 2H19e 2019e 1H20e 2H20e 2020e Perpetual Investments Revenue ($m) Costs ($m) EBITDA ($m) Closing FUM ($ billion) Average FUM ($ billion) Margin (%) 0.76% 0.74% 0.71% 0.73% 0.75% 0.72% 0.74% 0.74% 0.73% 0.73% 0.74% 0.73% 0.73% Private Wealth Revenue ($m) Costs ($m) EBITDA ($m) Closing FUM ($ billion) Average FUM ($ billion) Margin (%) 0.84% 0.85% 0.86% 0.86% 0.91% 0.91% 0.91% 0.91% 0.91% 0.91% 0.91% 0.91% 0.91% Corporate Trust Trust revenue ($m) FS revenue ($m) Total revenue ($m) Costs ($m) EBITDA ($m) Closing FUM ($ billion) Average FUM ($ billion) Margin (%) 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% Group and Support Services Revenue ($m) Costs ($m) Remaining Trans. Synergies ($m) EBITDA ($m) SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Figure 3 - Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES Earnings revisions Following the March quarter update, we have downgraded our underlying EPS estimates by -2.9%, -9.5%, and -8.7% for FY18, FY19 and FY20 respectively. The changes are driven by lower share market and net-flow levels versus expectation. The ASX200 was down -5% during the period, and there was a lost institutional mandate which we see as one-off. Earnings Revisions FY18e FY18e (new) (previous) % Change FY19e FY19e (new) (previous) % Change FY20e FY20e (new) (previous) % Change EPS (adjusted) (cps) % % % Dividend ( ps) % % % Page 4
5 Perpetual as at 16 April 2018 Recommendation Buy Price $42.09 Target (12 months) $47.50 Perpetual (PPT) 16 April 2018 Table 1 - Financial summary Perpetual (PPT) Price Target (A$) Share Price (A$) Recommendation: Buy Market Cap (A$m) 1,961 INCOME STATEMENT VALUATION DATA Y/e June 30 ($m) e 2019e 2020e Y/e June 30 ($m) e 2019e 2020e Sales revenue Net profit adj ($m) Cost base Adjusted EPS (c) EBITDA EPS growth (%) -2% 7% 3% -2% 6% Depreciation & Amortisation P/E ratio (x) Equity Grant Amortisation CFPS (c) EBIT Price/CF (x) Net Interest DPS (c) Pre-tax profit Yield (%) 6.1% 6.3% 6.4% 6.5% 6.9% Tax Franking (%) 100% 100% 100% 100% 100% Adjusted profit EV/EBITDA (x) One-off items Price/book (x) Reported net profit NTA ($) CASHFLOW PROFITABILITY RATIOS Y/e June 30 ($m) e 2019e 2020e Y/e June 30 ($m) e 2019e 2020e EBITDA EBIT/sales (%) 37% 37% 38% 36% 37% Change in provisions Return on assets (%) 16% 17% 17% 16% 17% Working capital change Return on equity (%) 22% 22% 22% 21% 22% Net interest ROIC (%) 16% 17% 18% 17% 18% Tax paid ROIC ex structured products (%) 24% 26% 27% 27% 29% Other Dividend cover (x) Operating cashflow Effective tax rate (%) -28% -28% -28% -28% -28% Capex Investments LIQUIDITY AND LEVERAGE RATIOS Asset sales Y/e June 30 ($m) e 2019e 2020e Other Net debt/(cash) ($m) Investing cashflow Net debt/equity (%) -32% -37% -34% -37% -39% Change in borrowings Current ratio (x) Equity raised Dividends paid INTERIMS Other Half end December 31 ($m) 1H16 1H17 1H18 1H19e 1H20e Financing cashflow Sales revenue Net change in cash EBIT Cash at end of period Pre tax profit Adjusted profit BALANCE SHEET One-off items Y/e June 30 ($m) e 2019e 2020e Reported profit Cash Interim DPS (cents) Receivables Structured Products SEGMENTALS PPE Y/e June e 2019e 2020e Intangibles Other Perpetual Investments Total assets Revenue ($m) Payables Costs ($m) Debt EBITDA ($m) Provisions Closing FUM ($ billion) Structured Products Average FUM ($ billion) Other Margin (%) 0.76% 0.73% 0.74% 0.73% 0.73% Total liabilities Shareholders equity Private Total shareholders funds Revenue ($m) Costs ($m) W/A diluted shares on issue EBITDA ($m) Closing FUM ($ billion) Average FUM ($ billion) Margin (%) 0.84% 0.86% 0.91% 0.91% 0.91% Corporate Trust Trust revenue ($m) FS revenue ($m) Total revenue ($m) Costs ($m) EBITDA ($m) Closing FUM ($ billion) Average FUM ($ billion) Margin (%) 0.01% 0.01% 0.01% 0.01% 0.01% Group and Support Services Revenue ($m) Costs ($m) Remaining Trans. Synergies ($m) EBITDA ($m) SOURCE: BELL POTTER SECURITIES ESTIMATES Page 5
6 Recommendation structure Buy: Expect >15% total return on a 12 month view. For stocks regarded as Speculative a return of >30% is expected. Research Team Staff Member TS Lim Sam Haddad Chris Savage Title/Sector Head of Research Phone tslim shaddad csavage Hold: Expect total return between -5% Jonathan Snape jsnape and 15% on a 12 month view Tim Piper tpiper Sell: Expect <-5% total return on a 12 month view John Hester Tanushree Jain Financials Healthcare Healthcare/Biotech jhester tnjain Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet. TS Lim Lafitani Sotiriou Resources Peter Arden David Coates Analysts James Filius Alexander McLean Banks/Regionals Diversified Financials Resources Resources Analyst Analyst tslim lsotiriou parden dcoates jfilius amclean Such investments may carry an exceptionally high level of capital risk and volatility of returns. Bell Potter Securities Limited ACN Level 38, Aurora Place 88 Phillip Street, Sydney 2000 Telephone The following may affect your legal rights. Important Disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client s financial situation, particular needs and investment objectives ( relevant personal circumstances ), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. ANALYST CERTIFICATION Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Page 6
Platinum Asset Management (PTM)
24 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90
More informationOneVue Holdings (OVH)
24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)
More informationOneVue Holdings (OVH)
7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation
More informationAdacel Technologies (ADA)
9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously
More informationBWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES
9 February 2017 Analyst John O'Shea 613 9235 1633 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $4.80 Target (12 months) $5.73 (unchanged) Expected Return Capital growth
More informationNanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES
21 February 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) Growth Slowly Emerging In Europe Recommendation Hold (unchanged) Price $2.80 Target (12 months) $3.20
More informationChallenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES
14 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Challenger (CGF) Expanding the potential Recommendation Buy (unchanged)
More informationMayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.
29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89
More informationSurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns
26 November 20 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 SurfStitch (SRF) Shaping the Surf industry Recommendation Buy (unchanged) Price $2.06 Target (12 months) $2.65 (previously
More informationNanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES
16 January 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) US Market Continues To Expand Recommendation Hold (unchanged) Price $3.16 Target (12 months) $3.28
More informationCyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Cyclopharm (CYC) 5 March 2018 Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES
17 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 ANZ Bank (ANZ) Unquestionably strong 1Q17 Recommendation Buy (Hold) Price $30.21 Target (12 months) $33.25 (previously
More informationOsprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55
27 February 2017 Analyst John Hester 612 8224 2871 Authorisation Tanushree Jain 612 8224 2849 Recommendation Buy (unchanged) Price $0.415 Valuation $0.55 (unchanged) Risk Speculative GICS Sector Healthcare
More informationPremier Investments (PMV)
16 March 2018 Analyst Sam Haddad 612 8224 2819 Authorisation Tim Piper 612 8224 2825 Premier Investments (PMV) Key growth pillars all strong Recommendation Buy (unchanged) Price $15.27 Target (12 months)
More informationANZ Banking Group (ANZ)
1 May 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $27.47 Target (12 months) $30.20 (unchanged) GICS Sector Banks Expected Return Capital
More informationIPH Limited (IPH) Buy at the bottom
29 March 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 IPH Limited (IPH) Buy at the bottom Recommendation Buy (unchanged) Price $4.76 Target (12 months) $7.90 (unchanged) Expected
More informationAuswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps
24 August 2018 TS Lim 612 8224 2810 Authorisation Tim Piper 612 8224 2825 Recommendation Buy (unchanged) Price $5.71 Target (12 months) $6.20 (previously $5.80) GICS Sector Banks Expected Return Capital
More informationAeon Metals Limited (AML)
Analyst David Coates 612 8224 2887 Authorisation Stuart Howe 613 9235 1856 Speculative See key risks on Page 4 Speculative securities may not be suitable for retail clients 22 March 2019 Aeon Metals Limited
More informationFortescue Metals Group Ltd (FMG)
3 March 2017 Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Fortescue Metals Group Ltd (FMG) All about the iron ore price Recommendation Sell (unchanged) Price $6.62 Target
More informationWestgold Resources (WGX)
3 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.36 Target (12 months) $2.15 (unchanged) Expected Return Capital growth
More informationOsprey Medical (OSP)
18 October 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Osprey Medical (OSP) Harvey and Irma Curtail Growth Speculative See key risks on Page 5 and Biotechnology Risk Warning
More informationCommonwealth Bank (CBA)
10 February 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Commonwealth Bank (CBA) Ordeal and triumph Recommendation Buy (unchanged) Price $74.20 Target (12 months) $83.50 (previously
More informationNational Australia Bank (NAB)
6 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $30.39 Target (12 months) $32.50 (previously $30.00) Expected Return Capital growth
More informationBreaker Resources NL (BRB)
David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Speculative See key risks on Page 6. Speculative securities may not be suitable for retail clients 8 February 2019 Breaker NL (BRB) More
More informationMetals X Limited (MLX)
16 July 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.655 Target (12 months) $0.95 (previously $0.98) Expected Return Capital growth
More informationMetals X Limited (MLX)
5 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.515 Target (12 months) $0.90 (previously $0.95) Expected Return Capital
More informationNational Australia Bank (NAB)
29 March 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $25.62 Target (12 months) $29.50 (unchanged) Expected Return Capital growth 15.1%
More informationPeet Bonds (PPCHA) A yield uplift from fixed rate senior debt
4 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 (PPCHA) Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code Peet PPCHA Face value $100 Estimated
More informationMetals X Limited (MLX)
19 April 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.76 Target (12 months) $0.98 (previously $1.00) Expected Return Capital growth
More informationGalaxy Resources Ltd (GXY)
27 March 2018 Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Galaxy Resources Ltd (GXY) Mt Cattlin doing what it is meant to Recommendation Buy Price $3.16 Price Target $4.75
More informationGalaxy Resources Ltd (GXY)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $1.835 Valuation $3.35 (unchanged) -------------- Risk Speculative Expected Return Capital
More informationMesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt
7 March 2017 Analyst Tanushree Jain 612 8224 2849 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $1.90 Valuation $3.22 (previously $3.17) Risk Speculative GICS Sector Pharmaceuticals
More informationTech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e
22 March 2017 Analyst Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Tech Sector Key picks unchanged: IRI, APX, ADA & IFM Stock Price Target Rating ADA $2.37 $3.25 Buy ALU $7.41 $7.90 Hold
More informationPremier Investments (PMV)
4 April 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 Premier Investments (PMV) The Myers touch Recommendation Buy (unchanged) Price $14.20 Target (12 months) $17.65 (previously
More information7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date
6 July 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 William Spraggett 613 9235 1733 Whitefield Resettable Preference Shares (WHFPB) Authorisation John Gleeson 612 9255 7220
More informationBreaker Resources NL (BRB)
Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Recommendation Buy (unchanged) Price $0.315 Valuation $0.96 (previously $1.30) Risk Speculative GICS Sector Materials Expected
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.41 Valuation $0.88 (previously $1.00) Risk Speculative Expected Return Capital growth
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More informationFortescue Metals Group (FMG)
30 October 2015 Analyst David Coates 612 8224 2887 Authorisation John Hester 612 8224 2871 Recommendation Buy (Hold) Price $2.09 Target (12 months) $2.40 (unchanged) Expected Return Capital growth 14.8%
More informationSt George Mining Ltd (SGQ)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $0.225 Valuation $0.30 (previously $0.26) Risk Speculative Expected Return Capital growth
More informationWestgold Resources (WGX)
7 February 2017 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $2.25 Target (12 months) $2.60 Expected Return Capital growth 15.6% Dividend
More informationParagon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality
26 September 2014 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Paragon Care (PGC) Big Boxes, Big Opportunity Recommendation Buy (Initiation) Price $0.33 Target (12 months) $0.38
More informationPioneer Credit (PNC)
23 June 2014 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 Pioneer Credit (PNC) Helping not chasing Recommendation Buy (Initiation) Price $1.55 Target (12 months) $1.80 Expected
More informationStrike Energy Ltd (STX)
Analyst Peter Arden 613 9235 1833 Authorisation Stuart Howe 613 9235 1782 Recommendation Buy (unchanged) Price $0.115 Valuation $0.26 (previously $0.23) Risk Speculative Expected Return Capital growth
More informationRide the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
17 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code BELL POTTER SECURITIES LIMITED ACN
More informationPlatinum Asset Management
AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium
More informationMetals X Limited (MLX)
1 November 2016 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.38 Target (12 months) $2.10 (unchanged) Expected Return Capital growth
More informationMacquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS
23 November 2015 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Macquarie Group Capital Notes 2 (MQGPB) TS Lim 612 8224 2810 Fixed Interest Issue overview Issuer Issue
More informationIOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.
AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium
More informationBoart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index
More informationValue at the top end. Figure 1: Trading margins on debt and equity securities
17 February 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Steve Goldberg 612 8224 2809 Westpac Convertible Preference Shares (WBCPC) Fixed Interest Issue overview
More informationAspire Mining Ltd (AKM)
4 June 2012 Analyst Stuart Howe 613 9235 1782 Fred Truong 613 9235 1629 Authorisation Jonathan Snape 613 9235 1601 Aspire Mining Ltd (AKM) Ovoot PFS released Recommendation Buy (unchanged) Price $0.13
More informationAsset revaluation driven by almonds
Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationMesoblast (MSB) Major CHF catalyst next week, Time to get on board
9 November 2018 Analyst Tanushree Jain 612 8224 2849 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $2.18 Valuation $4.06 (previously $3.95) Risk Speculative GICS Sector Pharmaceuticals
More informationFigure 1: ASX listed debt redemptions Figure 2: Trading margins on debt and equity securities
8 February 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation (NABPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code NAB NABPE Face value $100
More informationSims Metal Management
AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m
More informationMEDICAL DEVELOPMENTS INTERNATIONAL LTD
MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08
More informationInsurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates
11 May 2018 RECOMMENDATIONS AUB Group (AUB) Rating HOLD Risk Low Price Target $14.50 Share Price $14.17 Steadfast Group (SDF) Rating HOLD Risk Low Price Target $2.80 Share Price $2.88 RESEARCH ANALYST
More informationSG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.
AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional
More informationEclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials
More informationUBS Investment Research Brambles Limited
UBS Investment Research Brambles Limited FY12 result: strong revenue momentum Result highlights strong revenue momentum Brambles FY12 result was slightly ahead of expectations, revealing 11% underlying
More informationFigure 1: Bell Potter fair value assessment. 2.40%: July 2018 Fixed Rate Senior Bond (OTC yield 6.00%)
13 August 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation John Gleeson 612 9255 7220 Fixed Interest Issue overview Issuer Issue ASX code Crown CWNHA Face value $100
More informationSilver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SIV AU Price (at 08:50, 21 Mar 2017 GMT) Neutral A$7.71 Valuation - PER A$ 6.68 12-month target A$ 6.68 12-month TSR % -7.4 Volatility Index Medium GICS sector Capital Goods Market cap A$m 278
More informationBank of Queensland Capital Notes (BOQPE) Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
23 November 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Bank of Queensland Capital Notes (BOQPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue
More informationNoni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts
Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of
More informationCardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market
More informationCOMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW
COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital
More informationWINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW
WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital
More informationAutomotive Holdings Group
AUSTRALIA AHG AU Price (at 06:14, 11 Aug 2016 GMT) Outperform A$4.61 Valuation - EV/EBITA A$ 4.09-4.63 12-month target A$ 4.36 12-month TSR % -0.2 Volatility Index Low GICS sector Retailing Market cap
More informationMotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts
Date Theme Company Update Company MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction We moderate to HOLD (from Buy) with a revised target of $2.36 p/share. We were previously encouraged
More informationFY18 RESULTS PERPETUAL LIMITED. Twelve months to 30 June Chris Green Interim Chief Executive Officer. Gillian Larkins Chief Financial Officer
30 August 2018 PERPETUAL LIMITED RESULTS Twelve months to 30 June 2018 Chris Green Interim Chief Executive Officer Gillian Larkins Chief Financial Officer ABN 86 000 431 827 CHRIS GREEN INTERIM CHIEF EXECUTIVE
More informationChallenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation
1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.29 Valuation $0.67 (previously $0.88) Risk Speculative Expected Return Capital growth
More informationPraemium (PPS) COMPANY REPORT. Quartermaster
10 October 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.45 SNAPSHOT Monthly Turnover $9.2mn Market Cap $162mn Shares Issued 399.6mn 52-Week High $0.54 52-Week
More informationAMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA AU Price (at CLOSE#, 19 Mar 213) Underperform A$5.7 Volatility index Low 12-month target A$ 4.99 12-month TSR % +3.6 Valuation - Sum of Parts A$ 4.68 GICS sector Insurance Market cap A$m 14,855
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationGenex Power (GNX) COMPANY REPORT. NAIF lined up for Stage 2
21 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $0.37 Share Price $0.31 SNAPSHOT Monthly Turnover $2.5mn Market Cap $91mn Shares Issued 303.9mn 52-Week High $0.43 52-Week
More informationQBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision
AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium
More information2009 Half Year Results. Analyst and shareholder briefing 18 February 2009
2009 Half Year Results Analyst and shareholder briefing 18 February 2009 Agenda Group highlights David Deverall Financial results Roger Burrows Outlook David Deverall 1 Agenda Group highlights David Deverall
More informationFund Managers. Aust. Fund managers review & rank AUSTRALIA. Event. Stock Views
AUSTRALIA 4 February 2016 Macquarie Securities (Australia) Limited Aust. Fund managers review & rank Event We review and rank the listed Australian under Macquarie Securities coverage, assessing fund performance,
More informationKingsgate Consolidated
AUSTRALIA KCN AU Price (at 6:11, 31 Jul 215 GMT) Underperform A$.67 Valuation A$ - DCF (WACC 12.%, beta 1.6, ERP 5.%, RFR 3.8%).3 12-month target A$.3 12-month TSR % -54.9 Volatility Index Very High GICS
More informationSeek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SEK AU Price (at 06:33, 07 Apr 2017 GMT) Outperform A$16.33 Valuation - Sum of Parts A$ 16.77 12-month target A$ 16.50 12-month TSR % +3.9 Volatility Index Low/Medium GICS sector Commercial &
More informationCENTREPOINT ALLIANCE LIMITED (CAF)
Low Return High Financial Results 25 August 2014 CENTREPOINT ALLIANCE LIMITED (CAF) ACTION & RECOMMENDATION Financial planning and SME insurance premium funding business Centrepoint Alliance (ASX code:
More informationTox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA TOX AU Price (at 05:10, 30 Nov 2016 GMT) Outperform A$2.34 Valuation - EV/EBITDA A$ 2.52-3.07 12-month target A$ 2.79 12-month TSR % +23.1 Volatility Index Medium GICS sector Commercial & Professional
More informationCochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA COH AU Price (at 06:47, 26 May 2015 GMT) Outperform A$88.66 Valuation A$ 81.19 - DCF (WACC 8.0%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 95.00 12-month TSR % +9.8 Volatility
More informationGeneration Healthcare REIT
AUSTRALIA GHC AU Price (at 06:13, 24 Aug 2015 GMT) Neutral A$1.65 Valuation - Sum of Parts A$ 1.51-1.59 12-month target A$ 1.59 12-month TSR % +1.8 Volatility Index Low GICS sector Real Estate Market cap
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationFisher & Paykel Healthcare
NEW ZEALAND FPH NZ Price (at 05:00, 10 Jul 2015 GMT) Outperform NZ$7.03 Valuation NZ$ 7.39 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.80 12-month TSR % +13.1 Volatility
More informationAPN Property Group (APD) Buy Share Price: A$0.41
APN Property Group (APD) Buy Share Price: A$0.41 Success in direct syndicates Target Price: A$0.51 Direct property syndicates have always been an integral part of the APN Property Group (APD) business.
More informationPraemium (PPS) COMPANY REPORT. Model performance
14 August 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.41 SNAPSHOT Monthly Turnover $9.5mn Market Cap $165mn Shares Issued 398.5mn 52-Week High $0.54 52-Week
More informationEarnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation
AUSTRALIA CBA AU Price (at 06:10, 10 Sep 2013 GMT) Neutral A$73.63 Valuation A$ - DCF (WACC 10.3%, beta 1.0, ERP 5.0%, RFR 5.5%) 50.40 12-month target A$ 66.15 12-month TSR % -5.0 Volatility Index Low
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The
More information16-Jan Jul Oct Apr Sep Feb Dec Aug Nov May-09
16-Mar-09 16-Apr-09 16-May-09 16-Jun-09 16-Jul-09 16-Aug-09 16-Sep-09 16-Oct-09 16-Nov-09 16-Dec-09 16-Jan-10 16-Feb-10 200 180 160 140 120 100 80 60 40 20 0 PJ 2014 2015 2016 2017 2018 2019 BG 90 60
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationMNF Group Limited (MNF)
MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market
More informationNIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA NHF AU Price (at 09:52, 02 Mar 2016 GMT) Outperform A$3.72 Valuation A$ 3.85 - DCF (WACC 8.5%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 2.5%) 12-month target A$ 4.00 12-month TSR % +11.7 Volatility
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More information